Dr Fiona Sewell


Programme Manager – Toxicology and regulatory sciences, human health effects

Email address


Fiona leads our programmes on toxicology and regulatory sciences focusing on human health effects. She is a member of the Innovation and Translation Group.

View Fiona's Office-led projects

NC3Rs publications

Prior H, Sewell F, Stewart J (2017) Overview of 3Rs opportunities in drug discovery and development using non-human primates. Drug Discovery Today: Disease Models. (in press) doi: 10.1016/j.ddmod.2017.11.005

Sewell F, Ragan I, Marczylo T, Anderson B, Braun A, Casey W, Dennison N, Griffiths D, Guest R, Holmes T, van Huygevoort T, Indans I, Kenny T, Kojima H, Lee K, Prieto P, Smith P, Smedley J, Stokes WS, Wnorowski G, Horgan G (2015) A global initiative to refine acute inhalation studies through the use of 'evident toxicity' as an endpoint: Towards adoption of the fixed concentration procedure.  Regulatory Toxicology Pharmacology. 73(3):770-9. doi:10.1016/j.yrtph.2015.10.018.

Sewell F, Burden N, Chapman K, Robinson V. (2015). Pioneering Better Science through the 3Rs: An Introduction to the National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs). Journal of the American Association for Laboratory Animal Science 54(2):198-208. No doi, click to view.

Burden N, Sewell F, Andersen ME, Boobis A, Chipman JK, Cronin MTD, Hutchinson TH, Kimber I, Whelan M. (2015). Adverse Outcome Pathways can drive non-animal approaches for safety assessment. Journal of Applied Toxicology 35(9):971-975 doi:10.1002/jat.3165

Sewell F, Burden N, Chapman K (2015). Testing Chemical Safety: What Is Needed to Ensure the Widespread Application of Non-animal Approaches? PLoS Biology 13(5):e1002156 doi:10.1371/journal.pbio.1002156

Sewell F, Chapman K, Baldrick P, Brewster D, Broadmeadow A, Brown P, Burns-Naas LA, Clarke J, Constan A, Couch J, Czupalla O, Danks A,DeGeorge J, de Haan L, Hettinger K, Hill M, Festag M, Jacobs A, Jacobson-Kram D, Kopytek S, Lorenz H, Moesgaard SG, Moore E,Pasanen M, Perry R, Ragan I, Robinson S, Schmitt PM, Short B, Lima BS, Smith D, Sparrow S, van Bekkum Y, Jones D. (2014). Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials. Regulatory Toxicology and Pharmacology.70(1):413-29. doi:10.1016/j.yrtph.2014.07.018

Chapman K, Sewell F, Allais L, Delongeas JL, Donald E, Festag M, Kervyn S,Ockert D, Nogues V, Palmer H, Popovic M, Roosen W, Schoenmakers A, Somers K, Stark C, Stei P, Robinson S. (2013) A global pharmaceutical company initiative: an evidence-based approach to define the upper limit of body weight loss in short term toxicity studies. Regulatory Toxicology and Pharmacology. 67(1):27-38 doi: 10.1016/j.yrtph.2013.04.003

For additional publications, see Fiona's ResearchGate profile.


PhD, Molecular Biology 
University of Leeds, 2005 - 2009
Therapeutic targeting of Fibroblast Growth Factor Receptor 3 (FGFR3) in urothelial cell carcinoma.